Analysts have been eager to weigh in on the Healthcare sector with new ratings on Progenics (PGNX) and Irhythm Technologies (IRTC).
Progenics (PGNX)
In a report issued on November 15, Kumaraguru Raja from Brookline Capital Markets maintained a Buy rating on Progenics, with a price target of $13. The company’s shares closed on Friday at $5.38, close to its 52-week low of $4.68.
According to TipRanks.com, Raja is a 1-star analyst with an average return of -5.6% and a 36.7% success rate. Raja covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics Ltd, Corbus Pharmaceuticals, and Acer Therapeutics Inc.
Currently, the analyst consensus on Progenics is a Strong Buy with an average price target of $12.33, implying a 129.2% upside from current levels. In a report issued on November 9, Jefferies also reiterated a Buy rating on the stock with a $10 price target.
.
See today’s analyst top recommended stocks >>
Irhythm Technologies (IRTC)
In a report issued on November 16, Sean Lavin from BTIG maintained a Hold rating on Irhythm Technologies. The company’s shares closed on Friday at $74.27.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 10.0% and a 57.1% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Irhythm Technologies with a $94.67 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
